[Antiarrhythmic effect of TJ0711]
Yao Xue Xue Bao = Acta Pharmaceutica Sinica
|June 26, 2014
Summary
The novel alpha/beta-blocker TJ0711 demonstrates significant antiarrhythmic effects in animal models. It reduces the incidence and duration of various arrhythmias, including ventricular tachycardia and fibrillation, without negatively impacting myocardial action potentials.
Area of Science:
- Pharmacology
- Cardiovascular Research
- Drug Discovery
Background:
- Arrhythmia remains a significant cause of mortality worldwide.
- Novel therapeutic agents with improved efficacy and safety profiles are needed.
- Alpha/beta-blockers offer potential antiarrhythmic properties.
Purpose of the Study:
- To evaluate the antiarrhythmic efficacy of the newly developed alpha/beta-blocker, TJ0711.
- To investigate the effects of TJ0711 on various animal models of cardiac arrhythmia.
- To explore the potential mechanisms underlying TJ0711's antiarrhythmic action.
Main Methods:
- Induction of arrhythmias using CaCl2, ouabain, and ischemia/reperfusion in animal models.
- Measurement of cardiac action potentials using the glass microelectrode technique in guinea pig right ventricular papillary muscles.
- Assessment of biochemical markers such as lactate dehydrogenase (LDH) and creatine kinase (CK) in rat serum.
Main Results:
- TJ0711 significantly prolonged the onset of CaCl2-induced arrhythmia and dose-dependently reduced ventricular tachycardia (VT), ventricular fibrillation (VF), incidence, and mortality in ischemia-reperfusion models.
- TJ0711 increased the ouabain doses required to induce various arrhythmias (PVC, VT, VF, CA) in a dose-dependent manner.
- TJ0711 did not significantly affect resting potential, action potential amplitude, or maximum depolarization velocity but showed a trend towards shortening action potential duration at high concentrations.
Conclusions:
- TJ0711 exhibits significant antiarrhythmic effects across multiple animal models.
- Its mechanism may involve beta1 receptor blockade, selective alpha1 receptor blockade, and reduction of intracellular calcium concentration.
- TJ0711 represents a promising candidate for the treatment of cardiac arrhythmias.
More Related Videos
Related Concept Videos
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
4.2K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
4.2K
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
2.9K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.9K
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
2.3K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.3K
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
2.7K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.7K
01:28Mechanism of Cardiac Arrhythmias
2.7K
Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
2.7K
01:18Dysrhythmias IV: Characteristics of Bradyarrhythmias
786
Bradyarrhythmias are cardiac rhythm disorders characterized by a slower-than-normal heart rate, typically defined as fewer than 60 beats per minute. Some of which are discussed here:Sinus BradycardiaSinus bradycardia presents a heart rate lower than 60 beats per minute, with a regular rhythm originating from the SA node. The ECG typically shows normal P waves preceding each QRS complex, a normal PR interval (0.12 to 0.20 seconds), and a normal QRS duration (0.06 to 0.10 seconds).First-Degree AV...
786